ABSTRACT
OBJECTIVE To evaluate the effectiveness， safety and economics of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer （NSCLC）， and to provide evidence-based reference for clinical drug use and decision. METHODS Retrieved from PubMed， Embase， the Cochrane Library， CNKI， Wanfang databases， VIP and Health Technology Assessment （HTA） related websites， HTA reports， systematic evaluation/meta-analysis and economic evaluations about Aidi injection combined with first-line chemotherapy for NSCLC were collected from the inception to Aug. 2022. After data extraction and quality evaluation， descriptive analysis was performed for the results of included studies. RESULTS A total of 16 pieces of literature were included， involving 1 piece of systematic review， 13 pieces of meta-analysis， 2 pieces of pharmacoeconomic studies. Compared with first-line chemotherapy， Aidi injection combined with first-line chemotherapy could improve response rate and disease control rate， prolonged survival time， improved survival quality， reduced the incidence of nausea and vomiting， leukocytopenia and thrombocytopenia， and improved immune function， but had controversial effects on liver and kidney function. With the payment threshold set by 3 times the national per capita GDP in 2019， Aidi injection combined with first-line chemotherapy had a more economical probability. CONCLUSIONS Aidi injection combined with first-line chemotherapy for NSCLC has good efficacy and safety， and has certain economic benefits. However， given the limited pharmacoeconomic studies included， the economic conclusions obtained need to be carefully interpreted.
ABSTRACT
Objective:To study the effect of Aidi injection （AD） on the expression of cytochrome P450 isoenzyme 1A2，2E1，3A2，2C11（CYP1A2，2E1，3A2，2C11）mRNA and protein in rats with N-nitrosodiethylamine （DEN） chemically induced primary hepatocellular carcinoma（HCC）. Method:Three healthy SD male rats were randomly selected as the blank group， and the remaining rats were treated with DEN intermittently induced primary hepatocellular carcinoma rat model. After success of the model， the rats were randomly divided into model group and AD group， with 3 rats in each group. The rats in the blank group and model group were intraperitoneally injected with 10 mL·kg<sup>-1</sup> saline， while those in the AD group were intraperitoneally injected with 10 mL·kg<sup>-1 </sup>AD once a day， a total of 14 d intervention. Real-time quantitative polymerase chain reaction（Real-time PCR） and Western blot were used to detect the mRNA and protein expressions of CYP1A2， CYP2E1， CYP3A2 and CYP2C11， respectively. Result:Real-time PCR results showed that after 14 days of drug administration， compared with the blank group， the mRNA expressions of CYP1A2， CYP2E1， CYP3A2 and CYP2C11 were all down-regulated in para-cancerous tissue （PCT） and cancerous tissue （CT） in model group， and there were significant differences （<italic>P</italic><0.05，<italic>P<</italic>0.01）. Compared with the model group， the mRNA expressions of the four subtype enzyme were significantly down-regulated in PCT in the AD group（<italic>P</italic><0.05，<italic>P<</italic>0.01）， while the mRNA expressions of the four subtype enzyme were significantly up-regulated in CT （<italic>P</italic><0.05）， and the expression was down-regulated overall. Western blot results showed that compared with the blank group， the protein expressions of CYP1A2， CYP2E1， CYP3A2 and CYP2C11 in CT of the model group were significantly down-regulated （<italic>P</italic><0.01）， and the protein expressions of CYP3A2 and CYP2C11 were significantly down-regulated in PCT （<italic>P</italic><0.01）. Compared with the model group， the protein expressions of CYP1A2， CYP2E1， CYP3A2 and CYP2C11 in CT and PCT were down-regulated in the AD group， but the differences were not statistically significant. Conclusion:AD can down-regulate the mRNA and protein expressions of CYP1A2， CYP2E1， CYP3A2 and CYP2C11 in rat liver tissues. In clinical use of AD， attention should be paid to drug interactions that may be caused by CYP450 enzyme inhibition.
ABSTRACT
OBJECTIVE@#To evaluate the effects of Aidi Injection (, AD) in combination with Western medical therapies (WMT) in patients with primary liver cancer (PLC).@*METHODS@#Randomized controlled trials (RCTs) comparing AD plus WMT with WMT alone were retrieved from inception to March 2013 by retrieving the literature database thoroughly and systematically. The extracted data from included studies were analyzed and synthesized by Review Manager 5.2 software. The Cochrane risk of bias tool was used to assess the quality of included studies, and Begg's and Egger's tests were used to evaluate the potential presence of publication bias. The studies were divided into 7 separate subgroups in terms of quality of life (QOL), recent chemotherapy and the incidence of leukocyte reduction. The subgroup analysis was applied to assess the heterogeneity between included researches, and the sensitivity analysis was used to weigh the stability of studies.@*RESULTS@#Twenty-four RCTs were included in this study. Compared with WMT used alone, AD as additional intervention was more effective on improving QOL (P<0.01), increasing short-term efficacy (P<0.01), prolonging life (P<0.05 or P<0.01), relieving clinical symptoms (P<0.01), and reducing adverse events (e.g. reduce white blood cell counts, P=0.002; reduce in platelet counts, P<0.01). Subgroup analysis showed that the hepatic artery interventions with AD was superior in improving QOL (P<0.01) and enhancing short-term response rates (P=0.007) and reducing white blood cell counts (P=0.0004) than hepatic artery interventions alone (P<0.01). The chemoembolization plus AD or the chemotherapy plus AD were both better than chemoembolization or the chemotherapy alone in improving the QOL and short-term response rate (P<0.05 or P<0.01).@*CONCLUSIONS@#AD in combination with WMT improves QOL in patients with PLC. Considering the inherent limitations of the included studies, further well-designed, rigorously performed, high-quality, and double-blinded RCTs with large sample sizes are needed.
ABSTRACT
Aim To investigate the effect of Aidi injec-tion (ADI) on the pharmacokinetics of doxorubicin (DOX) and doxorubicinol (DOXol) in rats. In addi-tion, to explore the clinical significance of ADI and DOX combination. Methods SD rats were divided in-to single and combined administration groups. The combined group was injected with DOX(7 mg·kg-1) after intraperitoneally treated with ADI (10 mL· kg-1,once a day for continuous 14 d),while the sin-gle group was injected with DOX and saline. The con-centration of DOX in plasma was determined by UPLC-MS method,and then the difference in pharmacokinet-ic parameters were compared. Results The determi-nation methods with good precision and stability were suitable for the assay of DOX and DOXol in biological samples. The pharmacokinetic parameters of DOX and DOXol had no significant difference in two groups. Conclusion There is no obvious effect of ADI on the pharmacokinetics of DOX.
ABSTRACT
OBJECTIVE:To evaluate therapeutic efficacy and safety of Aidi injection combined with S-1 for advanced gastric cancer systematically,and to provide evidence-based reference. METHODS:Retrieved from CJFD,Wanfang database,VIP, CBM,Cochrane Library,PubMed and EMBase,randomized controlled trials(RCTs)about Aidi injection combined with S-1(tri-al group) vs. S-1 alone (control group) for advanced gastric cancer were collected. Meta-analysis was conducted by Rev Man 5.3 software after data extraction and quality evaluation by risk bias evaluation tool of Cochrane Handbook Version 5.1.0. RESULTS:A total of 8 RCT were included,involving 690 patients. Results of Meta-analysis showed that there was no statistical significance in therapeutic efficacy of solid tumor between 2 groups [OR=1.19,95%CI(0.88,1.61),P=0.26]. The improvement rate of survival quality[OR=3.62,95%CI(2.48,5.30),P<0.001],immunoglobulin level [CD3:SMD=1.31,95%CI(1.06,1.56),P<0.001;CD4:SMD=1.71,95%CI(1.38,2.04),P<0.001;CD8:SMD=-1.46,95%CI(-1.68,-1.23),P<0.001;CD4/CD8:SMD=1.45,95%CI(1.14,1.76),P<0.001] in trial group was significantly higher than control group. The incidence of leukopenia [RR=0.52,95%CI (0.40,0.68),P<0.001],thrombocytopenia [RR=0.49,95%CI(0.36,0.67),P<0.001] and gastrointestinal disorder [RR=0.56,95%CI(0.43,0.71),P<0.001] in trial group were significantly lower than control group,with statistical significance. CONCLUSIONS:Compared to S-1 alone,S-1 combined with Aidi injection can not significantly improve therapeutic efficacy of solid tumor therapy, but can improve survival quality and immunity of patients,as well as reduce the occurrence of ADR.
ABSTRACT
Objective To investigate the clinical significance of intraperitoneal perfusion of IL-2 combined with Addi injection for ascites re-growth control after decompression of abdominal compartment syndrome induced by malignant ascites.Methods 69 patients with abdominal compartment syndrome induced by malignant ascites,after tube decompression and paracentesis,were given intraperitoneal perfusion therapy,and they were randomly divided into two groups.42 cases in the observation group were given with 0.9％ sodium chloride injection 50mL + IL-23 millions u and Addie injection 50-60mL,once a week,a total of 2-3 times;27 cases in the control group were given with 0.9％ sodium chloride injection 50mL and cisplatin 40mg,once a week,a total of 1-3 times.Results In the observation group,CR 25 cases (59.5％),PR 11 cases (26.2％),NC 6 cases (14.3％),the total effective achieved in 36 cases (85.7％).In the control group,CR 11 cases (40.7％),PR 6 cases (22.2％),NC 10 cases (37.0％),the total effective achieved in 17 cases (62.96％).The effective rate of the observation group was significantly better than that of the control group,there was statistically significant difference(x2 =4.78,P ＜ 0.05).The qualities of life of the observation group were improved,8 cases were stable,lower in 2 cases,the effective rate was 76.2％,which of the control group were improved,10 cases were stable,lower in 4 cases,the effective rate was 48.1％.The effective rate of the observation group was significantly better than that of the control group,there was statistically significant difference (x2 =5.70,P ＜ 0.05).Conclusion Intraperitoneal perfusion of IL-2 combined with Addi injection for ascites control after decompression of abdominal compartment syndrome induced by malignant ascites is a new method,which is worthy of clinical application.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of Aidi Injection () on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC), and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope.</p><p><b>METHODS</b>Totally 150 patients with NSCLC were randomly assigned to the control group, the intravenous group and the intratumor group by the random envelope method, 50 cases in each group. The patients were treated with NP regimen (2 cycles), NP regimen (2 cycles) plus Aidi intravenous injection, or NP regimen (2 cycles) plus Aidi intratumor injection with thoracoscope, respectively for 6 weeks. The clinical effificacy was observed based on Response Evaluation Criteria in Solid Tumors (RECIST) rules, the expression of P-gp in the tumor tissue was tested before, 3 and 6 weeks after treatment, the safety was evaluated by monitoring the toxicity in the process of treatment, and the progression-free survival (PFS) was measured.</p><p><b>RESULTS</b>Fifteen cases dropped out because of the irreconcilable conditions which had no relationship with the treatment, 4 in the control group, 5 in the intravenous group, and 6 in the intratumor group, respectively. Compared with the control group, the response rates (complete remission + partial response) and the disease control rates (complete remission + partial response + stable disease) were significantly higher, the P-gp expressions were significantly decreased after 3 and 6 weeks of treatment, and the Kaplan-Meier survival curves of PFS were significantly longer in the intravenous and intratumor groups (P<0.05 or P<0.01), and the intratumor group showed better effects than the intravenous group (P<0.05 or P<0.01). Compared with the control group, the occurrences of rash, nausea and leukocytopenia were signifificantly decreased in the intravenous and intratumor groups (P<0.05), but without signifificant difference between the intravenous and intratumor groups (P>0.05).</p><p><b>CONCLUSION</b>Aidi Injection not only improves the effificacy of NP regime, but also has the function of reducing adverse events and preventing against overexpression of P-gp induced by chemotherapy of NP regimen.</p>
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of Aidi injection combined with TP regimen in the treat-ment of non-small cell lung cancer. METHODS:62 patients with non-small cell lung cancer were randomly divided into control group and observation group,31 cases in each group. Control group received TP regimen alone,observation group additionally re-ceived 40 ml Aidi injection,dissolved in 500 ml 0.9% Sodium chloride injection by intravenous infusion. 21 d was a treatment course,and it lasted 4 courses. The level of inflammatory cytokines before and after treatment and post-treatment quality of life, short-term efficacy,patients’satisfaction and toxicity reactions in 2 groups were compared. RESULTS:After treatment,the level of inflammatory cytokines in 2 groups were significantly lower than before,and observation group was lower than control group, the differences were statistically significant (P<0.05). The effective rate of life quality (80.64%) and short-term efficacy (83.87%)in observation group significant were higher than control group(32.25%,64.52%,respectively),the differences were statistically significant (P<0.05). Satisfaction degree (96.77%) in observation group was significantly higher than control group (77.42%);and the incidences of thrombocytopenia,leukopenia,abnormal liver function were significantly lower than control group,the differences were statistically significant (P<0.05). CONCLUSIONS:Aidi injection combined with TP regimen shows good efficacy and little toxicity in the treatment of non-small cell lung cancer,and it helps to reduce the level of inflammatory cyto-kines in patients,improving immune function and the quality of life of patients.
ABSTRACT
OBJECTIVE: To investigate the protective effects of aidi injection on cisplatin (CDDP)-induced acute nephrotoxicity in rats. METHODS: Forty male Sprague-Dawley rats were randomly divided into 5 groups, including the control group, CDDP group, the low, medium and high dose Aidi injection group (5, 10, 15 mL·kg-1). Except the rats in control group, the rats of other groups were injected with CDDP on the third day. Aidi injection groups were administered to the rats once daily for 7 consecutive days. The control and CDDP groups were given corresponding regime of saline. On the eighth day, determine the content of serum creatinine (Scr) and blood urea nitrogen (BUN) in the rat, detect the level of superoxide dismutase (SOD), glutathione reductase (GSH-Px) and malondialdehyde (MDA) in the kidney tissue; observe HE staining slices of rats and find the renal pathological changes. RESULTS: Compared with control group, the levels of Scr, BUN and MDA content were increased significantly in CDDP group, whereas the contents of SOD and GSH-Px were decreased significantly. There were serious, renal tubular epithelial cell apoptosis and inflammation in the kidney tissue. Kidney histopathology indicated that Aidi injection alleviated CDDP-induced tissue damage. The levels of Scr, BUN were decreased significantly in the low dose Aidi injection group, whereas the activity of SOD and GSH-Px were increased significantly. The medium dose of Aidi injection could increase the level of SOD and GSH-Px. The high dose of Aidi injection could enhance the activity of GSH-Px, without statistically significant effect on other indicators. CONCLUSION: The results indicate that the low and middle dose of Aidi injection might protect the renal tissue from nephrotoxicity induced by cisplatin through anti-oxidation.
ABSTRACT
Objective To observe the clinical efficacy of ModifiedYigongsan Formula combined with Aidi-injection on advanced gastric cancer.Methods Totally 64 cases of patients with advanced gastric cancer were randomly divided into treatment group and control group with 32 cases in each group. Both groups were treated with Aidi-injection for intravenous drip, continuous infusion for 2 weeks. The treatment group was treated with Modified Yigongsan Formula, daily 1 agent, oral administration after lunch, for 4 weeks continuously; the control group did not take other medicine. The tumor markers (CEA, CA199), TCM syndrome score and physical condition score of the patients before and after treatment were observed.ResultsAfter treatment, the TCM syndrome score in the treatment group was significantly improved than that in the control group; the total effective rate was 84.38% (27/32) in the treatment group, and 43.75% (14/32) in the control group; the treatment group was significantly higher than that in the control group (P0.05). Conclusion ModifiedYigongsan Formula combined with Aidi-injection on advanced gastric cancer tumor marker improvement was not obvious, but the improvement of TCM syndrome and physical condition of patients is very obvious.
ABSTRACT
OBJECTIVE:To provide reference for promoting clinical rational use of Aidi injection. METHODS:Some inpa-tient records that used Aidi injection in our hospital from Jan. to Jun. 2015 were randomly selected and statistically reviewed by us-ing Excel(2011 edition) in aspects of gender,age,tumor location,usage and dosage,solvents usage,treatment course,adverse reactions,etc. RESULTS:In the 125 patients who used Aidi injection,male was more than female,with average age of 58.4 years;the tumor location of 66 patients (52.80%) was consistent with the indications in instructions;treatment course of 30 pa-tients(24.00%)was consistent with the instructions;all solvent types were consistent with the instruction recommendation,while only 6 patients(4.80%)showed consistence in solvent usage and instructions;122 patients(97.60%)showed consistence in single dosage and instructions;7 patients had adverse reactions,mainly rash and gastrointestinal reactions. CONCLUSIONS:The use of Aidi injection in our hospital shows off-label drug use,non-standardized treatment course and inappropriate solvent usage. Physi-cians,clinical pharmacists and relevant departments should further strengthen the rational use,medical advice comments,supervi-sion and management of Aidi injection in the hospital to promote the rational drug use.
ABSTRACT
Objective To observe the radiosensitization effect of Aidi injection on human lung adenocarcinoma A549 cells, and to analyze its possible mechanism.Methods ① A549 cells were treated with different concentrations of Aidi injection (1.875, 3.75, 7.5, 15, 30, 60 mg/mL) for 24 hours, and in the mean time, a blank control group was set up; the effect of Aidi injection on lung adenocarcinoma A549 cells proliferation was detected by methyl thiazolyl tetrazolium (MTT) assay, and the 10% cell growth inhibitor concentration (IC10) was calculated. ② The experiments were divided into blank control, Aidi control, radiation and Aidi pretreatment groups. The Aidi control group was incubated for 24 hours by Aidi injection IC10; the radiotherapy group was given X-ray irradiation of 4 Gy followed by incubation for 24 hours; the Aidi pretreatment group was incubated for 24 hours by Aidi injection IC10 and then given X-ray irradiation of 4 Gy; the blank control group received equal volume of normal saline and was incubated for 24 hours. The survival fraction (SF) value was detected by cell colony formation assay; the protein levels of the serine phosphorylation at 139 locus of histone (γ-H2AX protein), the key protein in homologous recombination repair pathway (Rad51 protein) and the cell autophage characteristic protein (LC3 protein) were detected by Western Blot; the formation of autophagosome was observed by transmission electron microscope.Results Aidi injection possessed the suppression of the growth of human lung adenocarcinoma A549 cells, the proliferation of the cells in various Aidi groups was lower than that in the blank control group, with the increase in drug concentration, the A549 cell growth inhibition ratio (IR) was gradually increased, representing a dose dependent manner, and the IC10 was 3.09 mg/mL. Compared with the blank control group, the SF value in Aidi control group was not significantly different [(94.7±3.85)% vs. (100.0±0.00)%,P > 0.05], the SF value in radiation group was decreased [(71.8±5.9)% vs. (100.0±0.0)%,P < 0.05], and in Aidi pretreatment group, the value was further decreased compared with that in radiation group [(51.9±4.7)% vs. (71.8±5.9)%,P < 0.05]. Compared with the blank control group, the expression of γ-H2AX protein in the three treatment groups was significantly increased, the degree of increase in Aidi pretreatment group was the most obvious, and it was significantly higher than that in radiation group (gray value: 1.44±0.11 vs. 0.93±0.09,P < 0.05). But the expression of Rad51 protein was the highest in radiation group, and it was higher than that in Aidi pretreatment group (gray value: 1.37±0.07 vs. 0.78±0.04, P < 0.05). Compared with the blank control group, the LC3Ⅱ/LC3Ⅰ value in Aidi control group, radiation group and Aidi pretreatment group were increased, and the degree of increase in Aidi pretreatment group was the most significant (0.35±0.06, 0.37±0.07, 0.49±0.06 vs. 0.05±0.04, allP < 0.05). Under transmission electron microscope, compared with the blank control group, the autophagosome in all treatment groups was increased to some extent, and the degree of increase in Aidi pretreatment group was the most remarkable.Conclusion Aidi injection has the enhancing effect of radiosensitization on human lung adenocarcinoma A549 cells, and its mechanism is possibly related to the up-regulation of A549 cell autophagy level.
ABSTRACT
Objective:To study the short-term effects,toxic side effects and immune function of Aidi injection adjuvant GP methods chemotherapy for advanced non-small cell lung cancer(NSCLC).Methods:130 patients with advanced NSCLC were divided into study group and the control group according to treatment methods.The study group were given Aidi injection +GP,and the control group only treated with GP.The short-term effects,toxic side effects gradeⅢ-Ⅳand immune function changes were compared between the two groups.Results:The overall response rate was 40.28%in study group,higher than 37.93% in control group(P>0.05).The two groups showed differences in the rates of leucocyte decrease,gastrointestinal reaction and platelets decrease(P0.05),while in the control group the levels of CD4,CD8 and CD4/CD8 changed more significantly than before(P<0.05).The two groups also produced differences in CD4,CD8 and CD4/CD8 after treatment( P<0.05 ) .Conclusion: The short-term effects of Aidi injection adjuvant GP chemotherapy regimen for advanced NSCLC is similar to only GP chemotherapy,but it can obviously reduce the incidence of toxic side effects and prevent the immune func-tion.
ABSTRACT
Objective To evaluate the treatment effect of Lobaplatin combined with Aidi Injection on patients with advanced NSCLC, and observe the influence on the level of serum VEGF by the treatment. Methods 60 patients, with advanced NSCLC and malignant pleural effusion, were divided into two groups (observation group and control group) randomly, with 30 cases in each group. All patients were treated with thoracentesis and inserted central venous catheter for the drainage of pleural effusion. After exhaustion of pleural effusion, the control group was treated with Lobaplatin by pleural perfusion, and the observation group was treated with Aidi Injection in addition to the treatment on control group. The treatment, side effects and quality of life and the level of serum VEGF were compared. Results After treatment, it is significant that clinical effects, side effect and KPS score of living quality of the observation group was better than that of the control group (P<0.05). The level of serum VEGF was significant lower than that before treatment in both groups (P<0.05). The decrease of VEGF serum level in the observation group was significantly lower than the decrease in the control group (P <0.05). Conclusion Lobaplatin combined with Aidi Injection was one of the effective method for the treatment of NSCLS with malignant pleural effusion, and was worthy of clinical application.
ABSTRACT
Objective To evaluate the effects of Aidi injection on the short-term curative effect,pain level,quality of life and the survival time for the elderly and infirm patients with advanced cancer.Methods A total of 143 elderly patients with advanced cancer were randomly divided into two groups,71 patients in control group were treated with routine support therapies,and 72 patients in treatment group were injected with 50-60 ml Aidi injection infused in NS 250 ml by i.v drip every day combined with routine medicines,each cycle was 21 days,all patients were received for 2 cycles.Results After treatment the short-term curative effect rate (CR+PR) was 2.8 ％ (2/72) only compared with no effect of control group.But the effective and stabilization rate (CR+PR+SD) was 66.7 ％ (48/72),it was 31.0 ％ (22/71) in control group.There was significant difference between the two groups (P ＜ 0.05).The overall effective rate of easement of pain was 67.7 ％ (48/72) in treatment group versus 36.1％ (13/36) in control group (P ＜ 0.05).The median survival time (MST) was 6.2 months in treatment group versus 5.1 months in control group (P ＞ 0.05).The quality of life in treatment group was improved obviously (P ＜ 0.05).The side effects of patients in treatment group were very slight.Conclusions Aidi injection can reduce the cancer pain,improve the quality of life and prolong the survival time of the elderly and infirm patients with advanced cancer.It is safe,and effective to inhibit growth of tumor.It can be recommended widely to clinical use.
ABSTRACT
Objective To investigate the curative effect of Aidi injection solution combined withcarboplatin on controlling malignant pleural effusion(MPE).Method A total of 86 cancer patients with appearedPME were selected as our subjected who hospitalized in the First People's Hospital of Shangqiu from Feb.2012to Mar.2013.They were randomly divided into the observation group(43 cases) and the control group(43cases).Patients in the oontrol group were treated with carboplatin at dose of 100 mg/per times which was putinto the thoracic cavity,and patients in the observation group was treated with Aidi injection solution at dose of100 mg/per times beside carbeplatin.The treatment period was 4 weeks.The effect information,quality of lifeand adverse reactions were recorded.Results The total effective rate and survival quality improvement rate inobservation group were 86.05％ (37/43) and 51.16％ (22/43),higher than those in control group (67.44％(19/43),30.23％ (13/43)),and the differences were significant(x2 =4.170,3.903 ; P ＜ 0.05).There wasno significant difference in terms of the related adverse reactions between two groups(P ＞0.05).ConclusionThe therapy of Aidi injection solution plus carboplatin on controlling MPE is proved to be effective and it canimprove patients' quality of life with better safety.Therefore it is worthy of recommendation.
ABSTRACT
Objective To investigate the effectiveness of disodium Aidi injection for cancer-related fatigue in nasopharyngeal carcinoma patients of Ⅲ-Ⅳ B stage undergoing radiotherapy and chemotherapy.Methods Eighty nasopharyngeal carcinoma patients of Ⅲ-Ⅳ B stage with fatigue symptoms from December 2011 to May 2012 in our hospital were divided into two groups.All patients received treatment of sequential 3 cycles with platinum-based chemotherapy after concurrent chemoradiation.One group of 40 patients also received intravenous infusion of disodium Aidi injection (experimental group),the other group of 40 patients only received conventional therapy (control group).Brief fatigue inventory (BFI) questionnaires data were collected at baseline,the eighth week and the twentieth week after treatment.The changes of fatigue severity and the occurrence of Ⅲ-Ⅳ degree adverse reactions in the two groups were compared.Results At the eighth week,the improvement in fatigue severity was not significantly different between two groups (x2 =1.758,P =0.32).However,significant improvement in cancer-related fatigue of experimental group was found than that of control group at the twentieth week(x2 =8.12,P =0.005).The Ⅲ-Ⅳ degree adverse reactions of experimental group were significantly lower than that of control group.Conclusion Disodium Aidi injection combined with radiotherapy and chemotherapy can improve the cancer-related fatigue of nasopharyngeal carcinoma patients of Ⅲ-ⅣB stage and it can also reduce the incidence rate of Ⅲ-Ⅳ degree adverse reactions.
ABSTRACT
Objective To compare and analyze the effect of single PT (taxol,cisplatin) chemotherapy and the PT chemotherapy combined with Aidi injection in the medium and advanced esophageal patients,in order to maximize the strength chemotherapy' s effects,reduce the side effects,improve the patients' life qualities.Methods 106 cases of esophageal patients were randomly divided into two groups,53 patients for each group.The control group were treated by the single PT chemotherapy protocol,while the treatment group were combined with Aidi and PT chemotherapy protocol,21 days time peroid was taken as one circle.After two weeks,the effect,the patients' life qualities and the side effects between two groups were compared.Results The effective rates of treatment group and control group were 90.37 ％ (48/53) and 81.13 ％ (43/53),respectively,there was no statistic significance (P ＞ 0.05).The median-survival in two groups were 48 weeks and 42 weeks,which was statistic significance (P =0.027).The treatment group' s side effects incidence rate was lower than that of control group in Ⅲ-Ⅳ degree gastrointestinal reaction (Ⅲ degree P =0.026,Ⅳ degree P =0.027),Ⅲ-Ⅳ degree of inhibition of white blood cells (Ⅲ degree P =0.038,Ⅳ degree P =0.040),Ⅲ degree platelet inhibition (P =0.023) and Ⅱ-Ⅲ degree hypohemia (Ⅱ degree P =0.020,Ⅲ degree P =0.041).There were no statistically differences between treatment group and control group in liver,muscle,kidney toxicity and baldness (P ＞ 0.05).There were significant differences in Karnofsky score and body mass between pre-and post-treatment in chemotherapy group (P =0.067),but those in treatment group were not (P =0.006).Conclusion The Aidi injection combined with PT chemotherapy protocol has a better effect in the esophageal cancer patients,longer median survival time,reduced the side effects and improved the patients' life qualities,which is deserved to be used in the clinical furtherly.
ABSTRACT
ObjectiveTo investigate the chemical constituents from Aidi Injection.Methods The chemical constituents were isolated by chromatography on Sephadex LH-20 gel columns and reverse phase semi-preparative HPLC repeatedly.Their structures were identified by spectroscopic analysis (NMR and MS).ResultsTwenty-two compounds were isolated and identified to be 3-O-3',4'-diacetyl-β-D-xylopyranosyl-6-O-β-D-glucopyranosylcycloastragenol (1),astragaloside IV (2),astragaloside Ⅱ (3),astragaloside I (4),isoastragaloside I (5),acetylastragaloside I (6),ginsenosid Re (7),ginsenoside Rf (8),ginsenoside Rg1 (9),ginsenoside Rb3 (10),notoginsenoside R4 (11),ginsenoside Rb1 (12),ginsenoside Rc (13),ginsenoside Rb2 (14),ginsenoside Rd (15),lucyoside H (16),3-O-ββ-D-glucopyranosyl(l→4)-β-D-glucopyranosyl(l→3)-α-L-rhamnopyranosyl (1→2)-α-Larabinopyranosyl oleanolic acid 28-O-α-L-rhamnopyranosyl(l→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside (17),3-O-β-D-glucopyranosyl(1→3)-α-L-rhamnopyranosyl [β-D-glucopyranosyl-(l→4)]-(l→2)-αt-L-arabinopyranosyl oleanolic acid 28-O-α-L-arabinopyranosyl(1→4)-β-D-glucopyranosyl(1→6)-β-D-glucopyranoside (18),syringin (19),elentheroside E (20),4-(1,2,3-trihydroxypropyl)-2,6-dimethoxyphenyl-I-O-β-D-glucopyranoside (21),and coniferin (22).ConclusionCompounds 1-6 are originated from Astragalus membranceus,compounds 7-18 are originated from Panax ginseng,and compounds 19-22 are originated from Acanthopanax senticosus by LC-MS analysis.Compound 1 is a new compound.
ABSTRACT
Objective To explore and compare the therapeutic effects of Fufangkushen injection and Aidi injection on improving quality of life for patients with advanced lung cancer. Methods 60 patients in late stage of lung cancer with pathological diagnosis were split into two groups randomly. 30 patients in Kushen group received Fufangkushen injection plus base therapy, 30 patients in Aidi group received Aidi injection plus base therapy.The data was analyzed on term of tumour size,clinical symptoms,Karnofsky score,cancer marker CA125,CEA,before and after treatment in two groups.The therapeutic effects were evaluated after two circles of treatment. Results Compared the short term therapeutic effect, Kushen group had the stability rate for 83.3 ％(25/30),and 80.0 ％(24/30) for Aidi group.There was no significant difference.(P＞0.05).Compare the clinical therapeutic effect,Kushen group had the improving rate for 83.3 ％(25/30),and 80.0 ％(24/30) for Aidi group.There was no significant difference(P＞0.05).Compare the Karnofsky score,two groups had equal increasing stability rate (P＞0.05). Compare decreasing ratio of CEA and CA125 after treatment in two groups,there was no significant difference (P＞0.05). Conclusion Fufangkushen injection and Aidi injection both have acceptable therapeutic effects in the treatment of patients with later stage lung cancer.The result is equal. As well as they have some other characters themselves to improve lung cancer related symptoms. Fufangkushen injection is better to improve symptoms of heat toxin, and Aidi injection is better to improve symtoms of deficiency Qi. For Fufangkushen injection, it can also adjust disorder of liver function and relieve pain.